Atella Clinical Research LLC — research payments reported

By program year

4 rows

Year	Kind	Amount	Payments
2024	Research	$993	1
2023	Research	$1,915,593	6
2022	Research	$1,934,306	28
2021	Research	$184,270	8

Breakdown

Who paid Research payments · program years 2021–2024

Bavarian Nordic A/S $3,439,822 25 payments
Regeneron Pharmaceuticals, Inc. $364,053 3 payments
Pfizer Inc. $228,289 14 payments
Abbott Laboratories $3,000 1 payment

Studies the money was for Research payments · program years 2021–2024

Nct05238025 $1,887,288 21 payments
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age $1,552,534 4 payments
A Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Patients With COVID-19 $364,053 3 payments
An Interventional Efficacy and Safety Phase 23 Doubleblind 2Arm Study to Investigate Orally Administered Pf07321332ritonavir Compared With Placebo in Nonhospitalized Symptomatic Adult Participants With Covid19 Who Are at Increased Risk of Progressing to Severe Illness $227,255 12 payments
Peridot $3,000 1 payment
A Phase 23 Randomized Doubleblind Doubledummy Placebo Controlled Study to Evaluate the Safety and Efficacy of 2 Regimens of Orally Administered PF 07321332Ritonavir in Preventing Symptomatic Sarscov2 Infection in Adult Household Contacts of An Individual With Symptomatic Covid19 $1,034 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.